-
Dorsomorphin 2HCl for AMPK Causality
2026-09-05
Dorsomorphin 2HCl helps distinguish AMPK association from AMPK-dependent protection in metabolic assays, while also enabling BMP and iron-homeostasis studies. This workflow translates a recent probiotic–liver study into practical formulation, control, timing, and troubleshooting decisions.
-
Mono-ADP-Ribosylation Marks PARP7 and AHR for Degradation
2026-09-04
The reference study shows that blocking ubiquitylation or proteasomal turnover exposes endogenous ADP-ribosylated proteins that are otherwise rapidly degraded. It identifies DTX2 as the E3 ligase controlling degradation of ADP-ribosylated PARP7, AHR, and related substrates, establishing mono-ADP-ribosylation as a physiologically relevant degradation signal.
-
Nicotine Signaling in Chronic Kidney Disease
2026-09-04
This review synthesizes clinical and experimental evidence that nicotine contributes to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, hemodynamic changes, and pro-fibrotic signaling. Its principal contribution is a mechanistic framework linking smoking-associated renal deterioration to nicotine biology while distinguishing nicotine effects from the broader chemical complexity of cigarette smoke.
-
PA-824: From Nitro-Reduction to TB Assay Design
2026-09-04
PA-824 is a bicyclic nitroimidazole derivative whose activity links mycolic-acid disruption with respiratory collapse in Mycobacterium tuberculosis. This article explains how that biology should shape phenotype-aware assays, combination studies, and interpretation of drug-tolerant populations.
-
v-Agatoxin-IVA and N-Type Ca Channel Selectivity
2026-09-03
Sidach and Mintz showed that v-Agatoxin-IVA, widely used as a high-selectivity P-type calcium channel probe, can also produce incomplete, low-affinity blockade of neuronal N-type currents. The work demonstrates why toxin concentration, channel gating, and cellular context must be considered when assigning pharmacological channel identities.
-
Engineering a Focused Bitespiramycin Producer
2026-09-02
The reference study used an in-frame partial deletion of the sspA 3-O-acyltransferase gene to redirect a complex bitespiramycin biosynthetic profile toward 400-isovalerylspiramycin I. Its strain-engineering strategy illustrates how targeted tailoring-enzyme disruption can simplify antibiotic composition and improve the interpretability of downstream production and susceptibility studies.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-09-02
Pladevall-Morera and colleagues used an ATRX-stratified drug screen to identify receptor tyrosine kinase and PDGFR inhibitors as selectively more toxic to ATRX-deficient high-grade glioma cells. The study also shows that combining these inhibitors with temozolomide may enhance treatment response, supporting ATRX status as a relevant variable in translational studies and clinical-trial analyses.
-
Cefoperazone Sodium Salt: Assay Workflows
2026-09-01
Build more informative antimicrobial experiments with Cefoperazone sodium salt by combining MIC, MBC, β-lactamase-stratified testing, and biliary-matrix models. This practical guide covers preparation, assay design, comparative interpretation, and troubleshooting for gram-negative bacterial research.
-
Staurosporine: Designing Interpretable Death Assays
2026-09-01
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor widely used to induce apoptosis and interrogate cancer signaling. This guide presents a context-aware assay framework that distinguishes kinase perturbation from cell-death response, with practical implications for cancer research and liver disease models.
-
Nadolol (SQ-11725) in Cardiovascular Research
2026-08-31
Nadolol (SQ-11725) combines non-selective beta-adrenergic receptor blockade with a useful transporter and tissue-distribution question for cardiovascular models. This workflow shows how to connect beta-adrenergic signaling pathway assays with exposure measurements, controls, and troubleshooting for more interpretable hypertension research, angina pectoris studies, and vascular headache research.
-
BX795 PDK1 Inhibitor Workflows for Kinase Research
2026-08-31
BX795 combines nanomolar PDK1 activity with experimentally useful TBK1 and IKKε engagement, making it valuable for separating kinase signaling, cancer phenotypes, and innate immune readouts. This workflow-centered guide explains how to apply it without confusing pathway inhibition, cytostasis, and cell death.
-
Selective Autophagy Tunes IRF3 Stability
2026-08-30
Wu and colleagues show that CALCOCO2/NDP52-dependent selective autophagy removes IRF3 in a virus-load-dependent manner, while PSMD14 preserves IRF3 by editing its ubiquitin signal. The study defines a quality-control circuit that balances type I interferon production with immune suppression and offers a useful framework for analyzing transcription-factor turnover.
-
One-step TUNEL Cy3 Apoptosis Detection Kit Workflow
2026-08-29
Build a reproducible DNA fragmentation assay for tissue sections, adherent cells, suspension cells, and flow cytometry with a Cy3-based one-step workflow. Practical controls, quantitative readouts, and troubleshooting guidance help distinguish genuine apoptotic signaling from preparation artifacts.
-
ABT-199 Workflows for Mitochondrial Apoptosis
2026-08-28
Build sharper apoptosis assays with ABT-199 (Venetoclax), a highly selective BCL-2 probe for separating BCL-2 dependence from broad cytotoxicity. This workflow connects concentration-response profiling in lymphoma and AML models with the emerging evidence that RNA Pol II loss can actively signal to mitochondria.
-
EPZ5676: Practical DOT1L Inhibitor Workflows
2026-08-28
EPZ5676 combines subnanomolar biochemical potency with exceptional DOT1L selectivity, making it useful for both enzyme-level validation and cell-based epigenetic studies. This guide translates its mechanism into reproducible H3K79 methylation, leukemia cytotoxicity, and innate immune signaling workflows.